Pharmaceuticals & Biotechnology (India-Centric) — Q1 Fy27 Sector Synthesis (Investor Docs + Concall Intelligence)

This report synthesizes Q1 FY27 disclosures across Indian pharma, biotech, biosimilars, injectables, APIs, and CRDMO/CDMO players. The data shows a sector in structural growth (India branded formulations + specialty/complex products + biosimilars + CRDMO), but with sharp divergence by business model and exposure: (1) India branded formulation leaders are compounding with chronic mix upgrades and GLP‑1 momentum; (2) US generics are volatile with LOE cliffs, competition bursts, CGT/FTF exclusivity spikes, and settlement-driven amortization; (3) biosimilars are scaling but remain working-capital and launch-cycle heavy; (4) CRDMO shows lumpy demand and shipment timing shifts, while long-cycle capex is expanding capacity for peptides, fermentation, and biologics manufacturing.

A. Industry Overview & Market Landscape

A1) Sector Structure: “India Branded Core + Global Complex + Manufacturing Services”

Across the set, the sector divides into six overlapping archetypes:

1. India branded formulations (chronic-heavy): Sun, Torrent(+JB), Cipla, Lupin, Zydus, Mankind, Alkem, Ajanta, Ipca, GSK India, Glenmark (India).
2. US generics + complex generics/inhalation: Cipla, Lupin, Aurobindo, Dr. Reddy’s, Zydus, Glenmark, Alkem, Ipca/Unichem, Ajanta, Gland.
3. Biosimilars + biologics: Biocon, Zydus (biosimilar ADCs mentioned), Dr. Reddy’s (abatacept), Lupin (biosimilars pipeline),